Genetic variants and the risk of Crohn’s disease: what does it mean for future disease management?

Author： Török Helga-Paula   Glas Jürgen   Lohse Peter   Folwaczny Christian  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.7, Iss.12, 2006-08, pp. : 1591-1602

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapy of Crohn’s disease in childhood

By Beattie R Mark   Bremner A Ronald F  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 809-825

Informa Healthcare

Access to resources Recommend Favorite

Management of growth retardation in the young patient with Crohn’s disease

By Ballinger Anne  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 1, 2002-01 ,pp. : 1-7

Informa Healthcare

Access to resources Recommend Favorite

TNF- antagonists for the treatment of Crohn’s disease

By Kam L.Y.   Targan S.R.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 4, 2000-05 ,pp. : 615-622

Informa Healthcare

Access to resources Recommend Favorite

Toxicity of infliximab in the course of treatment of Crohn’s disease

By Bratcher Jason M   Korelitz Burton I  

Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. : 9-16

Informa Healthcare

Access to resources Recommend Favorite

Recent developments in the pharmacological treatment of Crohn’s disease

By Srinivasan Radhika   Lichtenstein Gary R  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 4, 2004-04 ,pp. : 373-391

Informa Healthcare

Access to resources Recommend Favorite